多血管病变合并2型糖尿病显著增加长期心血管风险:IMPROVE-IT试验二次分析
IMPROVE-IT试验事后探索性分析纳入18 144例急性冠脉综合征后稳定患者,随机接受辛伐他汀联合依折麦布或安慰剂,中位随访6年。依折麦布在各亚组中获益一致,高危亚组绝对风险降低数值更大。
要点
- 依折麦布在各亚组心血管风险降低一致,高危亚组绝对获益数值更大。
核心结论
- 在冠心病患者中,多血管病变或2型糖尿病均与长期心血管风险增加相关,两者合并风险叠加,形成极高危状态。
- 依折麦布在有无多血管病变和2型糖尿病的患者中获益一致,但高危患者可能获得最大绝对获益。
研究设计与样本
- IMPROVE-IT为多中心、双盲、随机、安慰剂对照试验,2005年10月26日至2010年7月8日于39个国家1158个中心招募。
- 18 144例年龄≥50岁、急性冠脉综合征后稳定患者随机接受辛伐他汀40 mg/日联合依折麦布10 mg/日或匹配安慰剂,中位治疗6年。
- 本分析为事后探索性分析,按基线多血管病变(外周动脉疾病或既往卒中/TIA)及合并2型糖尿病分层,评估预设终点。
主要发现
- 基线时1005例(6%)有外周动脉疾病,1071例(6%)有卒中或TIA;其中分别388例(39%)和409例(38%)合并2型糖尿病。
- 依折麦布在各组中一致降低心血管风险,最高危亚组绝对风险降低数值更大。
关键数值与推荐
- 主要复合终点包括心血管死亡、主要冠脉事件(非致死性心肌梗死、需住院的不稳定心绞痛或随机化后≥30天的冠脉血运重建)或卒中(缺血性或出血性)。
- 多血管病变定义为外周动脉疾病或既往卒中/短暂性脑缺血发作。
临床怎么用
- 对急性冠脉综合征后患者,应评估是否合并多血管病变和2型糖尿病,以识别极高危人群。
- 多血管病变合并2型糖尿病者风险叠加,可能需要更强化降脂等综合管理。
- 依折麦布联合他汀的获益在各亚组一致,高危患者绝对获益更大。
局限性
- 本分析为事后探索性分析,结果需谨慎解读。
- 多血管病变和2型糖尿病亚组样本量较小,可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute coronary syndrome, and assessed the effect of ezetimibe given on top of statin therapy in patients with these concomitant conditions. METHODS: IMPROVE-IT was a multicentre, double-blind, randomised, placebo-controlled trial assessing the effect of ezetimibe added to statin therapy after acute coronary syndrome. Recruitment was from Oct 26, 2005, to July 8, 2010, and the trial was done at 1158 sites in 39 countries. 18 144 patients aged 50 years and older who had been stabilised after an acute coronary syndrome were randomly assigned to 40 mg per day simvastatin plus either 10 mg per day ezetimibe or matched placebo, for a median duration of 6 years. In this post-hoc exploratory analysis, we assessed the prespecified endpoints of the trial, including the primary composite endpoint (cardiovascular death, a major coronary event [non-fatal myocardial infarction, documented unstable angina requiring hospital admission, or coronary revascularisation occurring at least 30 days after randomisation], or stroke [ischaemic or haemorrhagic]) by concomitant polyvascular disease at baseline (peripheral artery disease or previous stroke or transient ischaemic attack) and stratified by concomitant type 2 diabetes. Efficacy analyses were done according to intention to treat and event rates. IMPROVE-IT is registered with ClinicalTrials.gov, number NCT00202878. FINDINGS: 1005 patients (6%) had peripheral artery disease and 1071 (6%) had stroke or transient ischaemic attack at baseline. Of these, 388 (39%) and 409 (38%) also had concomitant type 2 diabetes, respectively. At 7 years, patients with either polyvascular disease or type 2 diabetes had similar rates of the primary endpoint (39·8% and 39·9%, respectively), which were higher than patients without polyvascular disease or diabetes (29·6%). Polyvascular disease with concomitant type 2 diabetes was associated with further heightened risk (60·0% 7-year Kaplan-Meier rate, adjusted hazard ratio versus those with polyvascular disease 1·60, 95% CI 1·38-1·85; p<0·0001). Ezetimibe reduced cardiovascular risk consistently across groups with greater numerical absolute risk reductions in the highest-risk subgroups. INTERPRETATION: In patients with coronary artery disease, concomitant polyvascular disease or type 2 diabetes are associated with increased long-term cardiovascular risk. The combination of polyvascular disease and diabetes is additive, resulting in very high risk. The benefit of ezetimibe is consistent in patients with and without polyvascular disease and type 2 diabetes; however, by nature of their higher risk patients with one, or especially both, of these diseases might derive the greatest absolute benefits. FUNDING: Merck.
引用
- Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018. PMID: 30396865. doi:10.1016/S2213-8587(18)30290-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。